C07K 2317/522
Ch1 domain
Official title: CH1 domain
C07K2317/522 (Ch1 domain) appears on 539 US grants and 1,193 published applications in this corpus.
Search patents in C07K- Granted patents
- 539
- Published applications
- 1,193
- Assignees
- 422
- Inventors
- 2,399
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 3 |
| 2007 | 0 | 4 |
| 2008 | 2 | 0 |
| 2009 | 1 | 12 |
| 2010 | 3 | 8 |
| 2011 | 4 | 10 |
| 2012 | 4 | 16 |
| 2013 | 8 | 35 |
| 2014 | 16 | 27 |
| 2015 | 14 | 38 |
| 2016 | 18 | 63 |
| 2017 | 30 | 78 |
| 2018 | 29 | 61 |
| 2019 | 36 | 75 |
| 2020 | 57 | 89 |
| 2021 | 53 | 119 |
| 2022 | 40 | 103 |
| 2023 | 55 | 117 |
| 2024 | 69 | 118 |
| 2025 | 61 | 124 |
| 2026 | 39 | 90 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Bispecific antibody simultaneously binding to interleukin-4 receptor alpha subunit and interleukin-5 receptor alpha subunit, encoding nucleic acids thereof and methods of use thereof for treatment29 Sep 2026US 12,747,297 B2Ajou University Industry-Academic Cooperation Foundation
- Methods and antibody compositions for tumor treatment29 Sep 2026US 12,747,300 B2Regeneron Pharmaceuticals, Inc.
- Bispecific antibodies with alternatively matched interchain cysteines and uses thereof15 Sep 2026US 12,735,481 B2Phanes Therapeutics, Inc.
- Bispecific antigen binding molecules targeting OX40 and FAP15 Sep 2026US 12,735,485 B2Hoffmann-La Roche Inc.
- Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use15 Sep 2026US 12,735,497 B2Hoffmann-La Roche Inc.
- Il12rb2 binding molecules and methods of use8 Oct 2026US 2026/0308265 A1Synthekine, Inc.
- Antibodies for use in canines1 Oct 2026US 2026/0297171 A1Invetx, Inc.
- Antibodies and uses thereof1 Oct 2026US 2026/0297188 A1LTZ Therapeutics Inc.
- Bispecific antigen binding molecule and use thereof1 Oct 2026US 2026/0297194 A1Shanghai Qilu Pharmaceutical Research and Development Centre Ltd.
- Method for treating systemic lupus erythematosus24 Sep 2026US 2026/0285964 A1Huabo Biopharm (Shanghai) Co., Ltd.
Most cited
By later US patents
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009
- Dual variable domain immunoglobulin and uses thereof187US 8,258,268 B2Abbott Laboratories · 2012
- Antibodies with modified isoelectric points139US 8,637,641 B2Xencor, Inc. · 2014
- Immunoglobulin variants and uses thereof90US 7,799,900 B2Genentech, Inc. · 2010
- Bivalent, bispecific antibodies84US 8,227,577 B2Hoffman-La Roche Inc. · 2012